Blogs

Explore our latest pharmaceutical and healthcare blogs for expert perspectives, strategic insights, and emerging trends across R&D, market access, digital health, and regulatory science—curated to inform, inspire, and empower your next move.

September 4, 2026

Evidence Without Context: Why Advanced Analytics Still Miss Commercial Reality

Advanced analytics has transformed how life sciences teams generate evidence.…

August 31, 2026

Beyond GLP-1s: Inside Obesity's $80 Billion Second Wave

The first wave of obesity innovation proved a simple point:…

August 30, 2026

ESMO 2026 Preview: What the Abstracts Reveal Before the Data Drops

Every major oncology congress has its headline moments: a trial…

August 13, 2026

How Patient Journey Analytics Improves Drug Commercialization

A drug's clinical trial data tells you how it performs…

August 12, 2026

Clinical Differentiation Is No Longer Enough: How "Access Differentiation" Is Becoming the Real Moat

A therapy can post best-in-class trial data and still stall…

August 11, 2026

Can Premium Pricing Survive in Rare Diseases? What 2026 Signals Say

For nearly two decades, rare diseases have lived in a…

July 30, 2026

Market Access Doesn't Begin After Approval. It Begins with Evidence

Why the most successful commercial launches are built long before…

February 17, 2026

Why Most RWE Fails Payer Scrutiny (and What Actually Passes)

Real-world evidence is no longer optional in market access discussions.…

February 5, 2026

The IRA Phase 2: What 2026 Price Negotiations Mean for Innovators, Biosimilars, and Global Launch Strategy

The Inflation Reduction Act (IRA) continues to reshape the U.S.…

February 3, 2026

The Collapse & Comeback of Digital Therapeutics: What the Industry Learned and Where It’s Going Next

For a few years, digital therapeutics were treated as inevitable.…

January 30, 2026

CGT Commercialisation 2.0: Ranking Markets by Regulatory, Infrastructure & Reimbursement Readiness

Cell and gene therapies are no longer a niche category.…